Cargando…

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors

BCR-ABL tyrosine kinase inhibitors, such as imatinib (Gleevec) are highly effective in treating human Philadelphia chromosome-positive (Ph(+)) chronic myeloid leukaemia (CML) in chronic phase but not in terminal acute phase; acquired drug resistance caused mainly by the development of BCR-ABL kinase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shaoguang, Li, Dongguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401291/ https://www.ncbi.nlm.nih.gov/pubmed/18205699 http://dx.doi.org/10.1111/j.1582-4934.2007.00108.x

Ejemplares similares

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
por: Quentmeier, Hilmar, et al.
Publicado: (2011)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

A Cell-Based Assay for Measuring Endogenous BcrAbl Kinase Activity and Inhibitor Resistance
por: Ouellette, Steven B., et al.
Publicado: (2016)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
por: Okabe, Seiichi, et al.
Publicado: (2013)

Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
por: Bucur, Octavian, et al.
Publicado: (2013)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
por: Okabe, Seiichi, et al.
Publicado: (2014)

A kinase-independent role for CDK8 in BCR-ABL1(+) leukemia
por: Menzl, Ingeborg, et al.
Publicado: (2019)

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia
por: Wagle, M, et al.
Publicado: (2016)

Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase
por: Choi, Eun-Ji
Publicado: (2023)

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach
por: Busch, Caroline, et al.
Publicado: (2023)

Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review
por: Al Hamad, Mohammad
Publicado: (2022)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells
por: Tsubaki, Masanobu, et al.
Publicado: (2017)

The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents
por: Liu, W M, et al.
Publicado: (2002)

Radotinib is an Effective Inhibitor of Native and Kinase Domain-Mutant BCR-ABL1
por: Zabriskie, Matthew S., et al.
Publicado: (2015)

Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold
por: Huang, Yen-Hua, et al.
Publicado: (2015)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
por: Cuellar, Sandra, et al.
Publicado: (2017)

Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
por: Shibata, Norihito, et al.
Publicado: (2018)

Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
por: Takeuchi, Asako, et al.
Publicado: (2020)

The Role of Mitochondrial DNA Damage and Repair in the Resistance of BCR/ABL-Expressing Cells to Tyrosine Kinase Inhibitors
por: Glowacki, Sylwester, et al.
Publicado: (2013)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
por: Cheng, Rubin, et al.
Publicado: (2021)

Development of protein degradation inducers of oncogenic BCR‐ABL protein by conjugation of ABL kinase inhibitors and IAP ligands
por: Shibata, Norihito, et al.
Publicado: (2017)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
por: Xie, Vicki, et al.
Publicado: (2018)

Bcr-Abl: one kinase, two isoforms, two diseases
por: Reckel, Sina, et al.
Publicado: (2017)

Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
por: Tanneeru, Karunakar, et al.
Publicado: (2013)

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
por: de Almeida, Maria Helena, et al.
Publicado: (2014)

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
por: Haguet, Hélène, et al.
Publicado: (2018)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity
por: Upshaw, Jenica N., et al.
Publicado: (2022)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors
por: Wang, Yihua, et al.
Publicado: (2023)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
por: Okabe, Seiichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fcj4nmpem4k8fnru6i8fcs3b4n